San Diego, United States
Gossamer Bio is a San Diego-based clinical-stage biopharmaceutical company, founded in 2015, that is dedicated to the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. With its slogan "Vision * Connection * Innovation," the company operates in the Biotechnology and Health Care industries and is headquartered in the United States.
The company recently secured a significant $212.00M in Post-IPO Equity investment on 20 July 2023, with notable investors including Boxer Capital, Invus, Nantahala Capital, Octagon Capital Advisors, Rock Springs Capital, Silverarc Capital, Palo Alto Investors, Federated Kaufmann Fund, Madison Avenue Partners, and Armistice Capital.
Gossamer Bio's singular focus on pulmonary arterial hypertension and the substantial recent investment signify a strong investor confidence in the company's potential to make a meaningful impact on the lives of individuals affected by this condition. The company's commitment to innovation and improving patient outcomes presents an exciting opportunity for venture capitalists seeking to support impactful healthcare solutions.
